

### The Republic of Tajikistan

## **Support for Vaccine: Rotavirus** This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: The Republic	of Tajikistan			
2.	Vaccine grant number:	15-TJK-08b-Y, 15 TJK-13b-X	15-TJK-08b-Y, 1517-TJK-13b-X, 18-TJK-13b-X, 19-TJK-13b-X, 20- TJK-13b-X		
3.	Date of Decision Letter:	30 September 20	19		
4.	Date of the Partnership F	ramework Agreement:	07 November	2012	
5.	Programme title:	New Vaccine Support (NVS), F	Rotavirus, Routine		
6.	Vaccine type:	Rotavirus			
7.	Requested product presentation and formulation of vaccine:				
	RV1, 1 dose/plastic tube, I	iquide			
8.	Programme Duration: 2015-2020				
9.	Programme Budget (indi	rogramme Budget (indicative): <sup>2</sup> (subject to the terms of the Partnership Framework Agreement)			
			2015-2019	2020	Total <sup>2</sup>
	Programme Budget (US\$	· · · · · · · · · · · · · · · · · · ·	5,751,838	1,070,000	6,821,838

#### 10. Vaccine introduction grant

Approval			
Year Grant Number		Amount (US\$)	
2015	15-TJK-08b-Y	203,000	

Disbursement			
Disbursement date	Amount (US\$)		
14 July, 2014	203,000		

#### 11. Product switch grant: Not applicable

(subject to the terms of the Partnership Framework Agreement) 12. Indicative Annual Amounts:3

Type of supplies to be purchased with Gavi funds	2015-2019	2020
Number of vaccine doses		454,800
Annual Amounts (US\$)	5,751,838	1,070,000

13.	Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
14.	Self-procurement:	Not applicable	
15.	5. Co-financing obligations:		

Co-financing obligations:

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the programme. <sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>&</sup>lt;sup>3</sup> This is the amount that Gavi has approved.



According to the co-financing policy, the Country falls within the group:

Initial self-financing phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023
Number of vaccine doses	76,500	-	-	-
Number of AD syringes	-	-	-	-
Number of re-constitution syringes	-	-	-	-
Number of safety boxes	-	-	-	-
Value of vaccine doses (US\$)	174,809	-	-	-
Total co-financing payments (US\$) (including freight)	179,500	-	-	-

#### 16. Operational support for campaigns: Not applicable

# 17. Additional Reporting Requirements:

		Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		
•	vaccine stock levels including buffer stock, by end of March;	31 March 2020
•	number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.	15 May 2020
•	Countries shall report the actual switch date in the first renewal request following the actual implementation.	
	ce with applicable Gavi processes, Country shall report on ic and financial performance.	To be agreed with Gavi Secretariat

Financial clarifications: Not Applicable

19. Other conditions: Not applicable

Signed by,

On behalf of Gavi

Thabani Maphosa

Managing Director, Country Programmes



30 September 2019